Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine

Abstract

Levorotatory and dextrorotatory enantiomers of 1-[(4-chlorophenyl)phenylmethyl]-4-[(4-methylphenyl)sulfonyl]piperazine of the formula their preparation and use for the preparation of substantially optically pure enantiomers of 1-[(4-chlorophenyl)phenylmethyl]piperazine, which are themselves valuable intermediate products for the preparation of optically active therapeutic compounds having a very high degree of optical purity.

What is claimed is:  
     
         1 . A method for the treatment of an allergic condition which comprises administering to a patient in need of such treatment an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, said treatment being conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.  
     
     
         2 . A method for the treatment of asthma which comprises administering to a patient in need of such treatment an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]acetic acid, said treatment being conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.  
     
     
         3 . A method for the treatment of inflammation which comprises administering to a patient in need of such treatment an effective amount of dextrorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid, said treatment being conducted in the absence of levorotatory dihydrochloride of 2-[2-[4-[(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid.  
     
     
         4 . A method according to  claim 1  wherein the administration is oral.  
     
     
         5 . A method according to  claim 1  wherein the administration is parenteral.  
     
     
         6 . A method according to  claim 1  wherein the administration is rectal.  
     
     
         7 . A method according to  claim 3  wherein the administration is topical.  
     
     
         8 . A method according to  claim 1  wherein the effective amount is in the range of from 0.5 to 100 mg per day.  
     
     
         9 . A method according to  claim 8  wherein the amount is in the range of from 2 to 20 mg per day.